Selection of Closed Transactions and CDD/VDD Projects
Explore our latest transactions alongside selected commercial and vendor due diligence (CDD & VDD) projects. Our team provides tailored transaction advisory services, acquisition insights, investment evaluations, and recommendations, supported by in-depth market analysis, competitive landscape reviews, and business plan assessments. With our expertise, you gain a clear view of opportunities and risks to maximize the value of your investments.
VDD Advisor: Mindful Capital Partners Completes the Sale of Sidam
Alira Health advised Mindful Capital Partners, an independent cross-border private equity firm focused on mid-market companies across Italy and the DACH region, in a Vendor Due Diligence engagement for Sidam, an Italian medical device company offering advanced solutions for the preparation, handling, and delivery of complex medical substances across several healthcare specialties.
CDD Advisor: Guala Closures Acquires KWK to Expand Into Pharmaceutical Closures
Alira Health advised Guala Closures, a global leader in specialty closure solutions, on a commercial due diligence engagement for its acquisition of KWK Kunststoffwerk Kremsmünster GmbH, an Austrian manufacturer of plastic caps and closures and precision dosing devices for the pharmaceutical and nutraceutical markets.
Read more
The transaction marks Guala Closures’ entry into pharmaceutical packaging and supports its innovation-driven growth strategy.
CDD Advisor: Partners Group Enters Strategic Investment Partnership to Support restor3d’s Growth
Alira Health advised Partners Group, a global private markets leader, in a Commercial Due Diligence for its strategic investment partnership with restor3d.
Read more
Founded in 2017, restor3d is a pioneer in technology-driven personalized orthopedic solutions, leveraging AI-powered design software, integrated additive manufacturing, and rapid surgical planning to deliver implants tailored to both surgeon preferences and patient anatomy.
CDD Advisor: Fremman Capital Acquires DIESSE Diagnostica Senese from Archimed
Alira Health advised Fremman Capital, a pan-European, mid-market investment firm with offices in London, Luxembourg, Madrid, Munich, and Paris, in a Commercial Due Diligence of DIESSE Diagnostica Senese, a leading producer of innovative diagnostic systems and dedicated reagents for the specialty In-Vitro Diagnostics market.
Read more
DIESSE Diagnostica Senese focuses mainly on diagnostics for autoimmune and infectious diseases, and hematology measurement systems. The company offers one of the broadest portfolios of specialty immunoassay tests in the market, with more than 170 tests available on its fully automated instruments.
CDD Advisor: Impact Expansion Invests in neurocare Group AG
Alira Health advised Impact Expansion on an investment into neurocare group AG. The Munich-based leader in personalized mental health care has partnered with Impact Expansion, a private equity firm focused on supporting companies with a strong social and environmental impact.
Exclusive Transaction Advisor: LINDIS Biotech License-out Korjuny (Catumaxomab) to Pharmanovia
Alira Health supported LINDIS Biotech in entering a license agreement with Pharmanovia for Europe for KORJUNY® (catumaxomab), indicated for the treatment of malignant ascites.
Read more
Catumaxomab was originally granted marketing authorization under the brand name Removab in the EU on April 20, 2009, for the treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is unavailable or no longer feasible. Catumaxomab was the first T-cell engager trifunctional antibody and the first drug in the world approved specifically for the treatment of malignant ascites. It has demonstrated safety and anti-tumor efficacy in more than 2,000 patients. The product has not been marketed since 2014 and was withdrawn from the EU on June 2, 2017, for commercial reasons.
On October 17, 2024, LINDIS Biotech GmbH received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the brand name KORJUNY®. Approval is expected by the end of 2024, making it the only drug treatment for malignant ascites.
M&A Sell-Side Advisor: Se Soigner Acquires MedicOeil from Hoya Corporation
Alira Health advised Hoya Corporation, a Japanese conglomerate specializing in ophthalmology, in the sale of its subsidiary, MedicOeil, to Se Soigner, a French healthcare provider. This transaction involved the divestiture of MedicOeil, a non-core business unit of Hoya, focused on managing ophthalmology clinics.
Read more
The sale to Se Soigner not only secures continued employment for the staff but also supports MedicOeil’s mission to enhance medical care accessibility in remote areas.
M&A Sell-Side Advisor: Gilero LLC Acquired by Sanner
Alira Health advised Gilero, a medical device design and manufacturing organization, in its acquisition by Sanner Group, a global leader in healthcare packaging solutions and a portfolio company of GHO Capital.
Read more
This strategic enhances Sanner’s product development capabilities and expands its presence in the U.S. market. The partnership is set to drive innovation and add value across the medical technology and drug delivery sectors. We were privileged to support Gilero in this process, ensuring a successful outcome.
Strategic and Financial Advisor: Klinge Biopharma GmbH enters into an exclusive licensing and supply agreement with MS Pharma
Alira Health has acted as the exclusive financial and strategic advisors to Klinge Biopharma GmbH, licensee and exclusive holder of the worldwide commercialization rights for FYB203, Formycon’s biosimilar candidate to Eylea® (Aflibercept), in the Middle East and North Africa.
CDD Advisor: TVM Capital Healthcare Invests in neurocare Group AG
Alira Health advised TVM Capital Healthcare on an investment into neurocare group AG. The Munich-based leader in personalized mental health care is set to receive a US$ 17 million boost from TVM Capital Healthcare, a specialist healthcare private equity firm.
CDD Advisor: Trill Impact Enters a Strategic Alliance with TT medic
Alira Health advised Trill Impact, a pioneering Impact House with around EUR 1.2 billion in assets under management, joining forces with TT medic GmbH, a medtech development and manufacturing partner for high-quality polymer components operating in Austria, Switzerland and Germany.
Advisor: CNX Therapeutics in the Commercial and Strategic Due Diligence of Two CNS Products Acquired from Eisai
Alira Health advised CNX Therapeutics, a UK-based specialty pharmaceutical company, in the Commercial and Strategic Due Diligence of two CNS products acquired from Eisai, Loxapac® and Parkinane LP®.
Read more
Addressing psychological disorders and Parkinson’s disease respectively, the acquisition of these two medicines will enable CNX Therapeutics to set up its presence in France while further strengthening its CNS portfolio.
Aesculapius Farmaceutici Srl sells to Ceres Pharma NV
Alira Health advised Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC drugs, food supplements and raw materials, in the sale to Ceres Pharma.
Read more
The transaction is expected to further expand Ceres Pharma’s presence in Italy and the business combination will create value for the pharmaceutical ecosystem via enhanced distributions and commercialization capabilities of the combined entity. We were honored to serve as a transaction advisor representing the seller in this landmark deal.
CDD Advisor: Alcami acquires Pacific Pharmaceutical Services
Alira Health advised Alcami, a leading Contract Development Manufacturing Organization headquartered in North Carolina, with CDD support in its acquisition of PPS, a West Coast-based biostorage company.
Read more
This investment will enable bicoastal geographic expansion of Alcami’s Pharma Storage and Services capabilities, thus allowing it to serve all US biotech and pharma hubs.
Exclusive transaction advisor: out-licensing agreements for EQL Pharma's Memprex in France and Germany
Alira Health supported EQL Pharma in entering licensing agreements for Memprex (methenamine hippurate-based products for prophylactic treatment of recurrent UTIs) with Laboratoires Majorelle and Dr.Pfleger, two local experts in women’s health and urology.
CDD Advisor: TVM Capital Healthcare invests in DEBx Medical
Alira Health advised TVM Capital Healthcare, a global specialist healthcare private equity firm headquartered in Dubai and Singapore, with CDD support in its multi-million euro investment in DEBx Medical, an Amsterdam-based medical devices company.
Read more
The investment will accelerate the introduction of the DEBx Medical solution, DEBRICHEM®, an innovative product for treating non-healing chronic wounds that is easy to use and highly effective in removing biofilm and curing hard-to-heal wounds.
Natech Plastic sells to Stratec SE
Alira Health advised Natech Plastic, a leading contract development and manufacturing company specialized in precision life sciences consumables, in the sale to Stratec SE.
Read more
The transaction is expected to boost Stratec’s presence in the North American market and the business combination will create value for the in-vitro diagnostics ecosystem via enhanced innovation and manufacturing capabilities. We were honored to serve as the sellers’ advisors in this important deal.
Exclusive buy-side advisor: Asahi Kasei acquires Bionova Scientific
Asahi Kasei Medical has finalized the acquisition of Bionova Scientific, a company specializing in contract development and GMP-compliant manufacturing services for biopharmaceutical companies. Alira Health represented the buyer in the transaction, contributing unique know-how of drug development, quality, and operations that was critical for the deal completion.
Exclusive sell-side advisor: Trelleborg acquires EirMed
Trelleborg Group has finalized the acquisition of EirMed, LLC, a company specializing in technical precision plastic injection-molded components for medical devices, including in-vitro diagnostics, minimally invasive surgery, and orthopedics. Alira Health represented the sellers in the transaction, playing a key role in managing the process and leading the deal to success.
Exclusive transaction advisor: several out-licensing agreements for EQL Pharma’s Mellozzan in Europe
Alira Health supported EQL Pharma on entering into several licensing agreements with renowned pharmaceutical companies with strong presence and providing important medicines for the treatment of ADHD.
Strategic advisor: BENVIC acquires LUC & BEL
With the acquisition of Luc & Bel, Benvic further strengthens its position in the medical sector. Luc & Bel is an Italian company specializing in the design and manufacturing of medical device components. Luc & Bel is now well-positioned to accelerate its growth with the many synergies and international presence of Benvic.
Advisor: Sagard NewGen invests in Laboratoires Delbert
Laboratoires Delbert’s recent capital raise of €40m supports its growth strategy and mission of keeping essential medicinal products on the market and available to patients around the world. Alira Health advised Sagard NewGen on this equity investment.
Exclusive strategic advisor: AGC Biologics acquires MolMed SpA
AGC Biologics has acquired MolMed SpA and is now one of the few companies offering both plasmid production and cell and gene therapy services. The Alira Health team played a key role in uniting these two innovative organizations, drawing on our CDMO and biomedical expertise.
Strategic advisor: GVS Filter Technology sells to Biomedical Innovations
GVS Filter Technology is one of the world’s leading manufacturers of filter solutions for applications in the healthcare and life sciences, energy and mobility, and health and safety sectors.
Strategic Advisor: GVS Filter Technology goes public
GVS Filter Technology’s initial public offering (IPOs) is the first on the Milan bourse’s main market in 2020 and the second-biggest in Europe, at 570 million euros.
Transaction advisor: Daiichi Sankyo sells LOPRESSOR®, ICAZ®, and MIOREL® to SIT Laboratorio Farmaceutico (DESMA HC Group)
This acquisition represents a significant elevation for DESMA HC Group in the French market and an opportunity for Daiichi Sankyo to optimize the allocation of its resources and focus on oncology within that market.
Buy-side advisor: Europlant Group acquires PlantExtrakt
Europlant’s acquisition of Plant Extrakt supports their geographical penetration into a region with high market potential. Europlant is a German developer and manufacturer of herbal pharmaceuticals and medicinal teas.
Buy-side advisor: SIFI acquires Dacudoses® and Novoptine ® from Gifrer Barbezat
This acquisition by SIFI, an Italian ophthalmic company, will accelerate its penetration into the French market—one of the largest and most competitive markets in Western Europe.
Strategic advisor: AsahiKASEI raises over $12M for Laminate
Laminate Medical Technologies has developed a vascular support device for dialysis patients. The capital raise round of over $12M will help Laminate in preparation of receiving FDA approval.
Transaction advisor: RICERFARMA and Cooper sign a distribution agreement
Cooper signs a distribution agreement with RICERFAMA for its brand Hyalugel, pioneer of hyaluronic acid in the field of dentistry.
Strategic Advisor: Pharmy II Laboratory sells to Ethypharm
The sale of Pharmy II Laboratory strengthens the Ethypharm Group’s commitment to pain management, expanding its portfolio to include six new drugs as well as pharmaceutical specialties in injectable and liquid form.
Exclusive financial advisor: Sequel Special Products sells to Nissha Co.
The sale of Sequel Special Products LLC brings Nissha Co. Ltd into the Medical Technologies segment. The acquisition provides Nissha Co. with new sales channels in contract manufacturing, increased production capacity, expanded product development and design functions to improve its value chain from development to production to sales.
Exclusive strategic and financial advisor: Röchling Group acquires Precision Medical Products, Inc.
With its acquisition of Precision Medical Products, Röchling will leverage the comprehensive contract manufacturing services to expand its position as a supplier of advanced medical technology products and to implement its growth strategy in the U.S.
M&A advisor: Mundipharma sells Limburg manufacturing site to Fidelio Healthcare
Mundipharma divested its Limburg manufacturing site as part of their operations restructuring in Germany. As part of the deal, Fidelio Healthcare will take over specific assets and Mundipharma will continue to produce in Limburg.
Strategic advisor: Lavipharm found a license partner for innovative transdermal Fentanyl
Lavipharm is the largest Greek pharmaceutical company that develops, manufactures, markets, and distributes pharmaceutical, cosmetic, veterinary, and consumer health products in Greece and internationally.
Strategic advisor: Life Partners Europe sells to Duomed Group
Alira Health supported Life Partners Europe, a manufacturer of medical, surgical, ophthalmic, and veterinary instruments and apparatus.
Strategic advisor: RyMed sells to Fresenius Kabi
RyMed Technolgies, LLC specializes in the development of safety products in the intravenous catheter care management field.
Strategic advisor: MNH acquires the medical waste management of Suez Group
Alira Health supported MNH in its strategy of becoming a French leader in the medical waste management through the acquisition of the medical waste management of Suez Group.
Strategic advisor: MNH acquires Réseau GC
Alira Health supported MNH in its strategy of becoming a French leader in the medical waste management through the acquisition of Group GC.